Advertisement
News
Advertisement

Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis

Tue, 05/24/2011 - 2:33am
Bio-Medicine.Org

NEW YORK, May 24, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis

http://www.reportlinker.com/p0284984/Triple-Analysis-Lung-Cancer-Lymphoma-and-Angiogenesis.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Lymphoma and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lung Cancer

The lung cancer report part includes defined and up to date development strategies for 283 lung cancer therapeutic drugs (>317 projects) within the portfolio of 167 investigators, from Ceased to Marketed. In total the report assesses three different sub-indications of lung cancer (Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Lung Cancer (general). This report part extensively analyses 182 identified targets of lung cancer drugs, organized into 173 drug target strategies, and assesses them in lung cancer.

This part is based on the following publication:

Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and

'/>"/>

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading